BSW Wealth Partners Has $800,000 Position in Novo Nordisk A/S (NYSE:NVO)

BSW Wealth Partners grew its position in shares of Novo Nordisk A/S (NYSE:NVO) by 2.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 9,296 shares of the company’s stock after buying an additional 213 shares during the period. BSW Wealth Partners’ holdings in Novo Nordisk A/S were worth $800,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the company. Xponance Inc. grew its position in shares of Novo Nordisk A/S by 27.6% during the 2nd quarter. Xponance Inc. now owns 2,665 shares of the company’s stock worth $380,000 after purchasing an additional 576 shares in the last quarter. AQR Capital Management LLC lifted its position in shares of Novo Nordisk A/S by 110.5% during the 2nd quarter. AQR Capital Management LLC now owns 17,164 shares of the company’s stock valued at $2,450,000 after acquiring an additional 9,012 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Novo Nordisk A/S by 2.2% in the second quarter. The Manufacturers Life Insurance Company now owns 131,876 shares of the company’s stock worth $18,824,000 after purchasing an additional 2,817 shares during the period. Sunbelt Securities Inc. raised its stake in Novo Nordisk A/S by 1.3% in the second quarter. Sunbelt Securities Inc. now owns 10,752 shares of the company’s stock valued at $1,535,000 after purchasing an additional 138 shares in the last quarter. Finally, EP Wealth Advisors LLC increased its holdings in Novo Nordisk A/S by 37.6% in the 2nd quarter. EP Wealth Advisors LLC now owns 65,844 shares of the company’s stock valued at $9,399,000 after buying an additional 17,982 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Analyst Upgrades and Downgrades

NVO has been the topic of several recent analyst reports. BNP Paribas upgraded Novo Nordisk A/S to a “strong-buy” rating in a research note on Monday, December 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, November 6th. UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. BMO Capital Markets cut their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research report on Monday, December 23rd. Finally, StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. One research analyst has rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $145.25.

Novo Nordisk A/S Stock Down 2.9 %

Shares of NYSE:NVO opened at $85.00 on Wednesday. The business has a fifty day simple moving average of $95.10 and a 200 day simple moving average of $114.43. Novo Nordisk A/S has a 12-month low of $78.17 and a 12-month high of $148.15. The firm has a market cap of $381.45 billion, a P/E ratio of 27.51, a P/E/G ratio of 0.90 and a beta of 0.45. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.